Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2023
2022
2021
2020
Profitability Metrics
Gross Margin
25.99%
Operating Margin
7.16%
Net Margin
20.70%
Efficiency Metrics
Revenue per Expense Ratio
1.08
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
29.43%
Income Tax Rate
30.25%
EPS
7.7100000000
Balance Sheet Analysis
Current Ratio
1.81
Cash Ratio
0.74
Working Capital
$700.30M
Debt to Equity
0.95
Debt to Assets
36.76%
Equity Ratio
38.67%
Cash Flow Analysis
Operating Cash Flow Ratio
11.73%
Free Cash Flow Ratio
8.62%
CapEx to Revenue
3.11%
Dividends Paid
$86.80M
Stock Buybacks
$36.40M
Total Shareholder Returns
$123.20M
Cash Position Change
6.64%
Key Takeaways (2023 FY)
Revenue declined by 7.4803497306368%, indicating potential market challenges
Increased dividend payments by 4.03%
Increased R&D investment by 6.36%
Detailed Growth Metrics
Core Performance
Revenue
-7.48%
Net Income
-8.90%
EPS
-8.79%
Operating Income
20.64%
Operational Efficiency
R&D Expenses
6.36%
SG&A Expenses
-7.59%
Operating Cash Flow
-49.40%
Free Cash Flow
-71.94%
Balance Sheet Health
Assets
-1.91%
Debt
-4.34%
Book Value per Share
-0.52%
Inventory
-6.90%
Shareholder Returns
Dividends per Share
4.03%
Shares Outstanding
-0.11%
Long Term Trends
3Y Revenue/Share
-4.13%
5Y Revenue/Share
-22.18%
3Y Dividend/Share
25.12%
5Y Dividend/Share
40.66%